Diabetes Care, Vol 22, Issue 1 33-37, Copyright © 1999 by American Diabetes Association

ARTICLES

Efficacy of metformin in the treatment of NIDDM. Meta-analysis

K Johansen
Hvidovre Hospital, University of Copenhagen, Denmark.

OBJECTIVE: The results differ concerning randomized controlled trials of the effects of metformin on blood glucose regulation and body weight. To get a systematic overview, a meta-analysis of the efficacy of metformin was performed by comparing metformin with placebo and sulfonylurea. RESEARCH DESIGN AND METHODS: All randomized controlled trials published since 1957 were selected by searching the Current List of Medical Literature, Cumulated Index Medicus, Medline, and Embase, Meta-analysis was performed calculating weighted mean difference (WMD) of fasting blood glucose, glycosylated hemoglobin, and body weight. RESULTS: Nine randomized controlled trials comparing metformin with placebo and ten comparing metformin with sulfonylurea were identified. The WMD between metformin and placebo after treatment for fasting blood glucose was -2.0 mmol/l (95% CI -2.4 to -1.7) and for glycosylated hemoglobin -0.9% (95% CI -1.1 to -0.7). Body weight WMD was not significant after treatment. Sulfonylurea and metformin lowered blood glucose and glycosylated hemoglobin equally, while there was a significant WMD of body weight (-2.9 kg [95% CI -4.4 to -1.1]) because of a 1.7-kg mean increase after sulfonylurea and a 1.2-kg mean decrease after metformin. CONCLUSIONS: Metformin lowers blood glucose and glycosylated hemoglobin significantly, compared with placebo. Metformin and sulfonylurea have an equal effect on fasting blood glucose and glycosylated hemoglobin, but the body weight is significantly lower after metformin compared with sulfonylurea treatment because of an increase in body weight after sulfonylurea treatment.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				W S A Smellie, N Shaw, R Bowley, M F Stewart, A M Kelly, P J Twomey, P R Chadwick, J B Houghton, J P Ng, and A J McCulloch Best practice in primary care pathology: review 10 J. Clin. Pathol., November 1, 2007; 60(11): 1195 - 1204. [Abstract] [Full Text] [PDF]

				G. A. Nichols, C. M. Alexander, C. J. Girman, S. J. Kamal-Bahl, and J. B. Brown Treatment Escalation and Rise in HbA1c Following Successful Initial Metformin Therapy. Diabetes Care, March 1, 2006; 29(3): 504 - 509. [Abstract] [Full Text] [PDF]

				B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]

				F. Zangeneh, Y. C. Kudva, and A. Basu Insulin Sensitizers Mayo Clin. Proc., April 1, 2003; 78(4): 471 - 479. [Abstract] [PDF]

				D. Kirpichnikov, S. I. McFarlane, and J. R. Sowers Metformin: An Update Ann Intern Med, July 2, 2002; 137(1): 25 - 33. [Abstract] [Full Text] [PDF]

				J. M. Miles, L. Leiter, P. Hollander, T. Wadden, J. W. Anderson, M. Doyle, J. Foreyt, L. Aronne, and S. Klein Effect of Orlistat in Overweight and Obese Patients With Type 2 Diabetes Treated With Metformin Diabetes Care, July 1, 2002; 25(7): 1123 - 1128. [Abstract] [Full Text] [PDF]

				S. E. Inzucchi Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review JAMA, January 16, 2002; 287(3): 360 - 372. [Abstract] [Full Text] [PDF]

				J. H. Scarpello Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes The British Journal of Diabetes & Vascular Disease, August 1, 2001; 1(1): 28 - 36. [Abstract] [PDF]

				P. Pozzilli and U. Di Mario Autoimmune Diabetes Not Requiring Insulin at Diagnosis (Latent Autoimmune Diabetes of the Adult): Definition, characterization, and potential prevention Diabetes Care, August 1, 2001; 24(8): 1460 - 1467. [Abstract] [Full Text] [PDF]

				J.-L. Chiasson and L. Naditch The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes Diabetes Care, June 1, 2001; 24(6): 989 - 994. [Abstract] [Full Text]

				L. S. Phillips, G. Grunberger, E. Miller, R. Patwardhan, E. B. Rappaport, and A. Salzman Once- and Twice-Daily Dosing With Rosiglitazone Improves Glycemic Control in Patients With Type 2 Diabetes Diabetes Care, February 1, 2001; 24(2): 308 - 315. [Abstract] [Full Text]

				R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]